MedTrace Logo

Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects

NCT04655872 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-02-25

No results posted yet for this study

Summary

This study is objective to evaluate the in vivo absorption, excretion and biotransformation pathways of \[14C\]-TPN171H in Chinese male healthy volunteers, and to reveal the overall pharmacokinetic characteristics of TPN171H in human body, so as to provide basis for rational use of the drug.

Conditions

  • Healthy Male Subjects

Interventions

DRUG

[14C]TPN171H

A single 10 mg oral dose of \[14C\]TPN171H containing approximately 100 microcurie of \[14C\]-TPN171H.

Sponsors & Collaborators

  • Shanghai Institute of Materia Medica, Chinese Academy of Sciences

    collaborator OTHER

  • Vigonvita Life Sciences

    lead INDUSTRY

Principal Investigators

  • Gangyi Liu · Shanghai Xuhui Central Hospital

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-26
Primary Completion
2021-01-27
Completion
2021-01-27

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04655872 on ClinicalTrials.gov